Lab-Grown Insulin Cells Show Promise in Early Type 1 Diabetes Study

Researchers in the Netherlands report early success using stem cells to create insulin-producing cells for transplantation. While results are encouraging, scientists emphasize the need for further research before this becomes a standard treatment.

News report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

In an early clinical study, most patients who received transplants of lab-grown insulin-producing cells no longer showed signs of diabetes one year later
The cells were created from pluripotent stem cells—cells capable of developing into many different cell types—grown in the laboratory
This approach could eventually provide an unlimited supply of insulin-producing cells, addressing a major limitation of current transplant methods
A key remaining challenge is preventing the body's immune system from rejecting the transplanted cells without requiring lifelong immunosuppressive medications
The research was published in The New England Journal of Medicine and is being accelerated by a new research center at Leiden University Medical Center

What the Study Found

An international research team has reported promising early results from a clinical study in which patients with Type 1 diabetes received infusions of insulin-producing cells grown from stem cells in the laboratory. According to the research, most study participants no longer had diabetes one year after receiving the transplant. The findings were published in The New England Journal of Medicine.

The insulin-producing cells were created using pluripotent stem cells—a type of cell that can develop into almost any cell type in the body. Researchers grew these cells in the lab and then transplanted them into patients with a complicated form of Type 1 diabetes.

How Type 1 Diabetes Develops

Type 1 diabetes is an autoimmune disease in which the body's immune system mistakenly attacks and destroys the insulin-producing cells (beta cells) in the pancreas. Without these cells, the body cannot regulate blood sugar levels. People with Type 1 diabetes must check their blood sugar multiple times daily and take insulin to stay healthy. Over time, the condition increases the risk of serious complications including cardiovascular disease and kidney disease.

Approximately 100,000 people in the Netherlands live with Type 1 diabetes.

Why This Approach Matters

Currently, one treatment option for Type 1 diabetes is islet transplantation, in which insulin-producing cells are extracted from donor pancreases and transplanted into patients. However, this approach has significant limitations: there is a critical shortage of donor organs, and the supply of available cells is finite.

Using stem cells to grow insulin-producing cells in the laboratory could overcome this bottleneck. 'Stem cells potentially offer a new and inexhaustible source of insulin-producing cells,' said Eelco de Koning, a professor and endocrinologist at Leiden University Medical Center (LUMC), in a statement about the research.

The work is being advanced by the Cure One LUMC research center, a new facility created to accelerate breakthroughs in this area.

The Road Ahead

While the early results are encouraging, researchers stress that much work remains before this becomes a standard treatment option. One major challenge is preventing the immune system from rejecting the transplanted cells. Currently, patients who receive islet transplants must take immunosuppressive medications for life to prevent rejection—a burden that researchers hope to eventually eliminate.

De Koning highlighted this priority: 'The next challenge is to enable transplantation without the need for lifelong immunosuppressive drugs.' Addressing this challenge will require additional research to understand how to make the transplanted cells "invisible" to the immune system or to better control immune responses.

Evidence label

Origin: universiteitleiden.nl (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.